Massive Bio to Unveil Drug Utilization Optimizer (DUO) at ASCO Annual Meeting 2024
2024年6月1日 - 9:00PM
ビジネスワイヤ(英語)
ASCO Annual Meeting – Massive Bio, pioneering leader in
AI-driven oncology solutions, is excited to announce the launch of
its latest product, Drug Utilization Optimizer (DUO), at the
upcoming ASCO Annual Meeting 2024. The innovative analytics and
real-time notification platform is designed to revolutionize how
pharmaceutical commercial teams target and engage with physicians,
providing unparalleled insights and efficiency.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240601692600/en/
Massive Bio to Unveil Drug Utilization
Optimizer (DUO) (Graphic: Business Wire)
Building on the success of the SYNERGY-AI platform, which excels
in anonymizing data, structuring documents, and matching patients
to over 14,000 cancer clinical trials in real time, DUO extends
Massive Bio's capabilities into the commercial realm. DUO is
specifically aimed at identifying potential opportunities for
pharma commercial teams to analyze the competitive landscape far
beyond outdated claims-based data, leveraging Massive Bio's
advanced analytics and data platform.
"Our new DUO platform is a game-changer for pharmaceutical
commercial teams," said Selin Kurnaz, PhD, Co-Founder and CEO of
Massive Bio. "By providing real-time, granular insights, DUO
empowers teams to connect with the right physicians and surface
relevant patients with unmatched efficiency, driving brand revenues
and reducing sales costs. Pharmaceutical companies have been
working with claims and de-identified data for a long time and
understanding real time patient journeys has been long over-due to
provide the most responsive access to drugs. Most importantly, when
a patient is under-genotyped, we support the patient to get tested
which means that we don’t see patients as data points on a map, we
operationalize the data so that patients get access to the enablers
(such as molecular diagnostics testing) to get access to the drug.
That is one of the reasons why we are miles different than
traditional real world data companies".
Key Features and Value Proposition of DUO:
AI-Enabled Oncology/Hematology Platform: Designed for
physician targeting with real-time insights, DUO helps commercial
teams identify key physicians and influence behavior at local,
regional, and country levels through a seamless platform.
Boost Brand Revenues & Cut Sales Costs: DUO enhances
brand revenues by 5-10% and reduces sales force costs by 10-15%
annually through superior physician targeting. For new,
competitive, and rare disease products, DUO delivers double the
value.
Unmatched & Growing Patient Insights: With over
120,000 cancer patients on board and 5-7k new patients added each
month, DUO offers deep clinical and genomic data for precision
physician targeting, surpassing traditional real-world data sources
reliant on claims or EMR data.
Identify Key Physicians & Influence Behavior: DUO
identifies physicians conducting Next Generation Sequencing (NGS)
or other diagnostics, surfacing these key influencers to pharma. It
also facilitates testing for patients in need, changing physician
behavior and delivering unparalleled value beyond traditional
real-world data companies.
Global Oncology Expertise: As a global oncology and
hematology company, Massive Bio blends clinical expertise with
technical prowess, offering a network of 4,600+ physicians and
unmatched data access.
"DUO is not just a tool; it's a transformative solution for
pharmaceutical commercial teams," said Dr. Arturo Loaiza-Bonilla,
MD MSEd, Co-Founder and Chief Medical Officer of Massive Bio. "By
harnessing the power of AI and real-time data, we are setting a new
standard in physician targeting and patient engagement."
We invite all stakeholders, especially pharmaceutical company
commercial teams, brand teams, and physician targeting teams, to
visit our booth (#29137) at ASCO 2024 for a demo of DUO. Discover
how DUO can drive your commercial success in oncology and
hematology.
For more information and to schedule a demo, please visit:
www.massivebio.com/clinical-network/
About Massive Bio:
Massive Bio’s vision is to cover the entire Pharma value chain
with disruptive solutions to improve entire ecosystem from drug
development to commercialization. Massive Bio is a unique
tech-enabled big data platform with multiple use cases — addressing
all friction points in end-to-end patient journey, enabling access
to advanced treatment options for patients and optimizing drug
commercialization for pharma. Utilizing AI to enhance equitable
access and precision targeting for clinical trial matching, drug
matching, and drug development, Massive Bio is committed to
breaking down barriers in clinical trial enrollment, fostering
value-based oncology decisions, and facilitating data-driven cancer
treatment. Serving over four dozen pharmaceutical companies,
contract research organizations, and hospital networks, Massive Bio
has earned recognition from the National Cancer Institute with an
SBIR contract, and it is founding member of CancerX Moonshot.
Founded in 2015 by a team of clinical, technology, and M&A
executives, Massive Bio boasts a global presence with nearly 100
people across 12 countries. For further details, please visit
www.massivebio.com, https://askfiona.ai, https://drarturo.ai or
interact with us on our social media channels.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240601692600/en/
Media: Massive Bio Erkan Terzi Chief Marketing Officer +1 844
627 7246 pr@massivebio.com